Nasdaq

Atea Pharmaceuticals Announces Continued Advancement of Global Phase 3 HCV Program with Dosing of First Patient in C-FORWARD Outside North America

C-FORWARD is the Second Phase 3 Trial in the Global HCV Development Program; the First Phase 3 Trial, C-BEYOND, is Currently Enrolling Patients in the US and Canada Regimen has Potential Best-in-Class ...
Seeking Alpha

Atea targets mid-2026 Phase III HCV results while expanding hepatitis pipeline and maintaining $329.3M cash runway

Management reiterated guidance that patient enrollment for the C-BEYOND trial will complete next month with top line results anticipated in mid-2026. Enrollment for C-FORWARD is expected to finish mid ...

Atea Pharmaceuticals Highlights Phase 3 HCV Timeline, Unveils New Hepatitis E Candidate AT-587 at JPMorgan Conference

Atea Pharmaceuticals (NASDAQ:AVIR) used its presentation at the 44th Annual JPMorgan Healthcare Conference to provide updates ...
Nasdaq

Atea Pharmaceuticals Launches Phase 3 C-FORWARD Trial for HCV Treatment Regimen Combining Bemnifosbuvir and Ruzasvir

Atea Pharmaceuticals has announced the initiation of the Phase 3 C-FORWARD trial, which evaluates the combination regimen of bemnifosbuvir and ruzasvir for treating hepatitis C virus (HCV). This trial ...
KTLA

New Report Offers Solutions to Maximize the Impact of the Housing Voucher Program

Research from RAND and the Terner Center, with support from the Cooper Housing Institute, demonstrates the effectiveness of the Housing Choice Voucher program and offers solutions to increase program ...